<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-2-10-04-2026-shutterstock_2006854028-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-2-10-04-2026-shutterstock_2006854028-430x241.jpg"/></p>
<p>羅氏將負責抗體選擇、連接、臨牀前和臨牀開發以及商業化。圖片來源：Melnikov Dmitriy / Shutterstock.com。</p>
<p>羅氏與 C4 Therapeutics 簽署了一項新的合作協議，旨在共同推進降解劑 - 抗體偶聯物（DACs）領域的研究，目標是引入一種新的癌症治療方式。</p>
<p>根據聯合研究計劃，兩家公司將合作開發針對未披露的腫瘤靶點的兩個 DAC 項目。</p>
<h3>深入瞭解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>LOA 和 PTSR 模型 - 單克隆抗體偶聯物 3 針對 Egfr...</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>LOA 和 PTSR 模型 - 單克隆抗體偶聯物 3 針對 Egfr...</h4>
<h5>深入瞭解 GlobalData</h5>
<p>商業智能的黃金標準。</p>
<p>瞭解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>發現高效的 B2B 營銷</h4>
<p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
<p>瞭解更多</p>
<p>C4 Therapeutics 將利用其 TORPEDO 平台進行降解劑載荷設計，而羅氏將負責抗體選擇、連接、臨牀前和臨牀開發以及商業化。</p>
<p>C4 Therapeutics 將獲得 2000 萬美元的預付款和額外的發現里程碑付款，潛在收益超過 10 億美元的監管和商業里程碑，以及未來銷售的分級版税。</p>
<p>C4 Therapeutics 總裁兼首席執行官 Andrew Hirsch 表示：“在過去十年中，C4T 與羅氏合作推動靶向蛋白降解的研究，並將這一方式確立為治療癌症的新方法。</p>
<p>“我們的新合作利用了 C4T 設計高催化性和選擇性降解劑的能力，以及 DACs 的降解劑載荷，同時結合了羅氏在開發具有特定結合能力的 ADC 方面的豐富經驗。”</p>
<p>“這些能力共同構建了一種強大的新方式，可以為患者提供變革性的藥物。”</p>
<p>羅氏企業業務發展負責人 Boris Zaïtra 表示：“羅氏早期就相信靶向蛋白降解及其潛在的差異化，在 2016 年首次與 C4T 合作時便已如此。</p>
<p>“我們與 C4 Therapeutics 的關係建立在十年的信任和共同的科學抱負之上。我們很高興進入第三次合作，擴展我們長期的夥伴關係，以開創 DACs 這一新興方式。”</p>
<p>2026 年 2 月，羅氏 獲得了美國食品藥品監督管理局的接受 其提交的 giredestrant 口服治療的新藥申請，以及與依維莫司聯合治療乳腺癌的申請。</p>

醫療業 ETF - SPDR

CCCC

紐交所高增長板生物技術指數 ETF - First Trust

<p>羅氏與 C4 Therapeutics 達成合作，以推進針對癌症治療的降解劑 - 抗體偶聯物（DACs）研究。羅氏將負責抗體的選擇、開發和商業化，而 C4 Therapeutics 將利用其 TORPEDO 平台進行藥物載體設計。該交易包括 2000 萬美元的預付款，以及超過 10 億美元的潛在里程碑和版税收入。這一合作建立在十年的合作基礎上，旨在開創癌症治療的新療法</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-2-10-04-2026-shutterstock_2006854028-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-2-10-04-2026-shutterstock_2006854028-430x241.jpg"/></p>
<p>Roche will manage antibody selection, conjugation, preclinical and clinical development, and commercialisation. Credit: Melnikov Dmitriy / Shutterstock.com.</p>
<div class="lb-trans"><p>羅氏將負責抗體選擇、連接、臨牀前和臨牀開發以及商業化。圖片來源：Melnikov Dmitriy / Shutterstock.com。</p>
</div><p>Roche has signed a new collaboration agreement with C4 Therapeutics to jointly advance research in the field of degrader-antibody conjugates (DACs), aiming to introduce a new therapeutic modality for cancer.</p>
<div class="lb-trans"><p>羅氏與 C4 Therapeutics 簽署了一項新的合作協議，旨在共同推進降解劑 - 抗體偶聯物（DACs）領域的研究，目標是引入一種新的癌症治療方式。</p>
</div><p>According to the joint research plan, the companies will partner on two programmes for developing DACs against undisclosed oncology targets.</p>
<div class="lb-trans"><p>根據聯合研究計劃，兩家公司將合作開發針對未披露的腫瘤靶點的兩個 DAC 項目。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入瞭解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>LOA and PTSR Model - Monoclonal Antibody Conjugate 3 To Target Egfr...</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - 單克隆抗體偶聯物 3 針對 Egfr...</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>LOA and PTSR Model - Monoclonal Antibody Conjugate 3 To Target Egfr...</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - 單克隆抗體偶聯物 3 針對 Egfr...</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入瞭解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商業智能的黃金標準。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>發現高效的 B2B 營銷</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p>C4 Therapeutics will use its TORPEDO platform for degrader payload design while Roche will manage antibody selection, conjugation, preclinical and clinical development, and commercialisation.</p>
<div class="lb-trans"><p>C4 Therapeutics 將利用其 TORPEDO 平台進行降解劑載荷設計，而羅氏將負責抗體選擇、連接、臨牀前和臨牀開發以及商業化。</p>
</div><p>C4 Therapeutics will receive a $20m upfront payment and additional discovery milestone payments, with potential to earn more than $1bn in regulatory and commercial milestones, plus tiered royalties on future sales.</p>
<div class="lb-trans"><p>C4 Therapeutics 將獲得 2000 萬美元的預付款和額外的發現里程碑付款，潛在收益超過 10 億美元的監管和商業里程碑，以及未來銷售的分級版税。</p>
</div><p>C4 Therapeutics president and CEO Andrew Hirsch said: “For the past decade, C4T and Roche have worked together to drive research in targeted protein degradation and to establish this modality as a new way to treat cancer.</p>
<div class="lb-trans"><p>C4 Therapeutics 總裁兼首席執行官 Andrew Hirsch 表示：“在過去十年中，C4T 與羅氏合作推動靶向蛋白降解的研究，並將這一方式確立為治療癌症的新方法。</p>
</div><p>“Our new collaboration leverages C4T’s ability to design highly catalytic and selective degraders, as well as degrader payloads for DACs, alongside Roche’s extensive experience developing ADCs with specific binding.”</p>
<div class="lb-trans"><p>“我們的新合作利用了 C4T 設計高催化性和選擇性降解劑的能力，以及 DACs 的降解劑載荷，同時結合了羅氏在開發具有特定結合能力的 ADC 方面的豐富經驗。”</p>
</div><p>“Together, these capabilities build a powerful new modality that can offer transformative medicines for patients.”</p>
<div class="lb-trans"><p>“這些能力共同構建了一種強大的新方式，可以為患者提供變革性的藥物。”</p>
</div><p>Roche corporate business development head Boris Zaïtra said: “Roche has been a believer in targeted protein degradation and its potential for differentiation early on, when partnering with C4T for the first time in 2016.</p>
<div class="lb-trans"><p>羅氏企業業務發展負責人 Boris Zaïtra 表示：“羅氏早期就相信靶向蛋白降解及其潛在的差異化，在 2016 年首次與 C4T 合作時便已如此。</p>
</div><p>“Our relationship with C4 Therapeutics is built on a decade of trust and shared scientific ambition. We are pleased to enter into our third collaboration, expanding our long-standing partnership to pioneer the emerging modality of DACs.”</p>
<div class="lb-trans"><p>“我們與 C4 Therapeutics 的關係建立在十年的信任和共同的科學抱負之上。我們很高興進入第三次合作，擴展我們長期的夥伴關係，以開創 DACs 這一新興方式。”</p>
</div><p>In February 2026, Roche obtained acceptance from the US Food and Drug Administration for its new drug application submitted for the giredestrant oral therapy, along with everolimus, to treat breast cancer.</p>
<div class="lb-trans"><p>2026 年 2 月，羅氏 獲得了美國食品藥品監督管理局的接受 其提交的 giredestrant 口服治療的新藥申請，以及與依維莫司聯合治療乳腺癌的申請。</p>
</div>

羅氏和 C4 Therapeutics 將推進降解劑 - 抗體偶聯物的研究